Overview
Tissue repair peptides have attracted intense research interest because they address one of medicine’s persistent gaps: the slow, unreliable healing of tendons, ligaments, and cartilage — tissues with poor blood supply and limited regenerative capacity. BPC-157 and TB-500 are the two most studied research compounds in this category, though both are now prohibited from 503A compounding by the FDA.
Key Mechanisms
Angiogenesis Promotion
Multiple repair peptides (BPC-157, TB-500, GHK-Cu) promote formation of new blood vessels into injured tissue, which is rate-limiting in tendon and ligament repair. BPC-157 appears to upregulate VEGF and VEGFR2.
Fibroblast Recruitment
Fibroblasts produce the collagen matrix that becomes repaired tissue. BPC-157 and TB-500 both promote fibroblast migration and activity.
Growth Hormone Axis
Sermorelin, CJC-1295, and Ipamorelin increase systemic GH and IGF-1 — growth factors with documented roles in muscle protein synthesis, bone density maintenance, and (less clearly) connective tissue repair.
Actin Cytoskeleton (TB-500)
Thymosin β-4 sequesters G-actin, regulating cell motility and migration critical for wound healing.
Evidence by Tissue Type
| Tissue | Best Evidence | Research Compound | Notes |
|---|---|---|---|
| Tendon | BPC-157 (rat models) | BPC-157 | Multiple studies showing accelerated tendon repair |
| Ligament | BPC-157 (rat/rabbit) | BPC-157 | Superior to control in multiple injury models |
| Muscle | TB-500 (animal) | TB-500 | RegeneRx Phase I completed; cardiac data most robust |
| Gut lining | BPC-157 (animal) | BPC-157 | Gut-brain axis effects; IBD models |
| Bone | GH secretagogues (human) | CJC-1295/Ipamorelin | Phase I data shows IGF-1 elevation |
| Cartilage | Limited data | Multiple | No strong data for any research peptide |
Regulatory Caveat (2023–2025)
Both BPC-157 and TB-500 were placed on the FDA’s 503A prohibited substances list in late 2023. They can no longer be legally compounded at US pharmacies. Their status as research chemicals remains intact — but that designation applies to research, not clinical therapy. Any clinic currently offering injectable BPC-157 or TB-500 is doing so outside regulatory compliance.